Navigation Links
DecisionView Enhances Market-Leading Clinical Enrollment Optimization Solution With Improved Cost Modeling
Date:1/10/2012

SAN FRANCISCO, Jan. 10, 2012 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer 4.4, the latest version of the company's flagship solution for patient enrollment planning, tracking and forecasting.

With new customer-driven features focused on cost modeling and visibility, the latest innovations in StudyOptimizer enable pharmaceutical companies to easily optimize the time and cost tradeoffs for their clinical trial enrollment plans. In addition, when studies go off track, these new features make it easy to model and estimate the cost of various rescue scenarios.

"In planning clinical trials, patient recruitment and enrollment is a major potential source of delays," said Alan Louie, Research Director at IDC Health Insights. "With as much as 50 percent of trial project plans requiring rescue and rework, the cost of inefficiency can be high."

By enabling clinical trial organizations to model and compare enrollment plans that trade off cost and timeline impacts, StudyOptimizer 4.4 provides a critical tool for optimizing clinical trials and bringing down drug development costs. The new release delivers the following compelling capabilities:

Trial Cost Modeling

  • Enhanced Cost Planning - StudyOptimizer 4.4 enables study planners to define enrollment and rescue scenarios using different cost and timeline assumptions, then easily compare these plans at the overall study and country level.
  • Improved Cost Tracking – StudyOptimizer 4.4 allows sponsors to track accrued and projected costs based on study progress. In addition, the new release keeps a complete audit trail and historical record of all cost changes within a study plan, so that organizations can assess why and when costs were updated, and to help inform future plan budgets for similar studies.
  • Modeling Cost Adjustments – StudyOptimizer 4.4 provides an improved ability to capture and model one-time or interval-based expenses, as well as incremental screening and treatment costs incurred over the duration of the study.

Additional Customer-Driven Enhancements

  • Improved Support for Adaptive Trials – StudyOptimizer 4.4 adds the ability to model "interim analyses," to determine their effect on plans and projections.
  • Improved Investigator Scorecards – StudyOptimizer 4.4 makes it easier to identify outstanding investigator performance through Gold Star scoring.

ABOUT DECISIONVIEW

DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, is a web-based solution that helps clinical trial organizations plan, forecast and track patient enrollment. DecisionView Enrollment Benchmarks aggregate cross-industry performance data from clinical trials that have completed enrollment, providing insight to enable more realistic planning and forecasting. DecisionView products are used by 8 of the top 10 global pharmaceutical companies, and have been used on over 1,250 clinical studies with over 450,000 subjects enrolled in 17 different therapeutic areas across 91 different countries. Investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to http://www.decisionview.com or call 415-538-1800.

 

Contact:

Bill McCue
North 6th Agency, Inc.
212-334-9767
bmccue@n6a.com


'/>"/>
SOURCE DecisionView Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
2. DecisionView to Create Clinical Trial Enrollment Benchmarks
3. DecisionView Launches StudyOptimizer(TM) 4
4. LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
5. CryoLife Enhances Management Team with Promotions
6. BSGI/MBI Enhances Pre-Surgical Planning For Patients With Newly Diagnosed Breast Cancer
7. Vermillion Enhances Management Team With A Key Addition
8. A Beautiful Smile Enhances Communication Skills
9. Study Shows That Salt Lake City Based Company Has Program That Enhances Brain Activity
10. BSI Enhances its Medical Device Training Curriculum with RABQSA Beginning in August
11. MedInformatix RIS Enhances Lenox Hill Radiologys Practice Management Efficiencies for Better Workflow and Improved Customer Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):